Fate Therapeutics Inc (FATE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $155.74M
Last updated: Nov 17, 2026 at 11:06 AM ET
Fate Therapeutics Inc (FATE) Earnings: Report Dates and Results
Fate Therapeutics (FATE) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Fate Therapeutics reported EPS of -$0.25, above the -$0.27 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
FATE has an expected report date of Feb 24, 2027.
Earnings History
Of the 40 quarters below that had an estimate, FATE beat 19, missed 18 and matched 3. The widest gap in the table came in the quarter ended Sep 30, 2020, when EPS landed 88.89% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.25 | -$0.27 | -$0.28 - -$0.21 | +7.41% | Beat | N/A | 8 | 4 up, 2 down | Nov 5, 2026 | N/A |
| Jun 30, 2026 | -$0.25 | -$0.28 | -$0.28 - -$0.22 | +10.71% | Beat | N/A | 9 | 1 up, 0 down | Aug 13, 2026 | $2.08M |
| Mar 31, 2026 | -$0.26 | -$0.28 | -$0.30 - -$0.25 | +7.14% | Beat | N/A | 8 | 1 up, 0 down | May 13, 2026 | $1.30M |
| Dec 31, 2025 | -$0.27 | -$0.27 | -$0.29 - -$0.25 | 0.00% | In line | N/A | 8 | N/A | Feb 26, 2026 | $1.37M |
| Sep 30, 2025 | -$0.27 | -$0.28 | -$0.37 - -$0.23 | +3.57% | Beat | N/A | 9 | 0 up, 1 down | Nov 13, 2025 | $1.74M |
| Jun 30, 2025 | -$0.29 | -$0.34 | -$0.44 - -$0.27 | +14.71% | Beat | N/A | 11 | 4 up, 1 down | Aug 12, 2025 | $1.91M |
| Mar 31, 2025 | -$0.32 | -$0.38 | -$0.43 - -$0.28 | +15.79% | Beat | N/A | 7 | 5 up, 0 down | May 13, 2025 | $1.63M |
| Dec 31, 2024 | -$0.44 | -$0.42 | -$0.49 - -$0.35 | -3.82% | Miss | N/A | 13 | 2 up, 7 down | Mar 5, 2025 | $1.86M |
| Sep 30, 2024 | -$0.40 | -$0.41 | -$0.66 - -$0.37 | +2.44% | Beat | N/A | 18 | 0 up, 0 down | Nov 12, 2024 | $3.07M |
| Jun 30, 2024 | -$0.33 | -$0.45 | -$0.64 - -$0.40 | +26.67% | Beat | N/A | 18 | 0 up, 0 down | Aug 13, 2024 | $6.77M |
| Mar 31, 2024 | -$0.47 | -$0.45 | -$0.67 - -$0.42 | -4.44% | Miss | N/A | 18 | 1 up, 0 down | May 9, 2024 | $1.93M |
| Dec 31, 2023 | -$0.45 | -$0.52 | -$0.71 - -$0.32 | +13.46% | Beat | N/A | 21 | 0 up, 0 down | Feb 26, 2024 | $1.68M |
| Sep 30, 2023 | -$0.46 | -$0.56 | -$0.76 - -$0.37 | +17.86% | Beat | N/A | 21 | 1 up, 0 down | Nov 8, 2023 | $1.94M |
| Jun 30, 2023 | -$0.54 | -$0.58 | -$0.78 - -$0.34 | +6.90% | Beat | N/A | 21 | 0 up, 0 down | Aug 8, 2023 | $933000 |
| Mar 31, 2023 | -$0.19 | -$0.62 | -$1.06 - -$0.15 | +69.35% | Beat | N/A | 21 | 0 up, 0 down | May 3, 2023 | $58.98M |
| Dec 31, 2022 | -$0.58 | -$0.86 | -$1.12 - -$0.56 | +32.56% | Beat | N/A | 24 | 1 up, 0 down | Feb 28, 2023 | $44.36M |
| Sep 30, 2022 | -$0.86 | -$0.87 | -$1.06 - -$0.77 | +1.15% | Beat | N/A | 22 | 0 up, 0 down | Nov 3, 2022 | $14.98M |
| Jun 30, 2022 | -$0.78 | -$0.81 | -$1.00 - -$0.65 | +3.70% | Beat | N/A | 22 | 0 up, 0 down | Aug 3, 2022 | $18.55M |
| Mar 31, 2022 | -$0.68 | -$0.74 | -$0.90 - -$0.63 | +8.11% | Beat | N/A | 19 | 0 up, 1 down | May 4, 2022 | $18.41M |
| Dec 31, 2021 | -$0.72 | -$0.67 | -$0.94 - -$0.41 | -7.46% | Miss | N/A | 19 | N/A | Feb 28, 2022 | $17.07M |
| Sep 30, 2021 | -$0.45 | -$0.55 | -$0.74 - -$0.41 | +18.18% | Beat | N/A | 16 | 3 up, 0 down | Nov 4, 2021 | $14.22M |
| Jun 30, 2021 | -$0.58 | -$0.52 | -$0.60 - -$0.41 | -11.54% | Miss | N/A | 14 | N/A | Aug 4, 2021 | $13.41M |
| Mar 31, 2021 | -$0.44 | -$0.43 | -$0.52 - -$0.31 | -2.33% | Miss | N/A | 15 | N/A | May 5, 2021 | $11.14M |
| Dec 31, 2020 | -$0.61 | -$0.39 | -$0.43 - -$0.34 | -56.41% | Miss | N/A | 16 | N/A | Feb 24, 2021 | $15.90M |
| Sep 30, 2020 | -$0.68 | -$0.36 | -$0.44 - -$0.31 | -88.89% | Miss | N/A | 15 | N/A | Nov 5, 2020 | $7.56M |
| Jun 30, 2020 | -$0.35 | -$0.29 | -$0.47 - $0.22 | -20.69% | Miss | N/A | 16 | N/A | Aug 5, 2020 | $5.46M |
| Mar 31, 2020 | -$0.44 | -$0.39 | -$0.45 - -$0.29 | -12.82% | Miss | N/A | 16 | N/A | May 11, 2020 | $2.52M |
| Dec 31, 2019 | -$0.37 | -$0.39 | -$0.48 - -$0.28 | +5.13% | Beat | N/A | 15 | N/A | Mar 2, 2020 | $2.80M |
| Sep 30, 2019 | -$0.40 | -$0.37 | -$0.41 - -$0.30 | -8.11% | Miss | N/A | 14 | N/A | Nov 5, 2019 | $2.43M |
| Jun 30, 2019 | -$0.36 | -$0.31 | -$0.39 - -$0.18 | -16.13% | Miss | N/A | 12 | N/A | Aug 6, 2019 | $2.82M |
| Mar 31, 2019 | -$0.30 | -$0.23 | -$0.27 - -$0.17 | -30.43% | Miss | N/A | 8 | N/A | May 7, 2019 | $2.63M |
| Dec 31, 2018 | -$0.25 | -$0.24 | -$0.34 - -$0.10 | -4.17% | Miss | N/A | 8 | N/A | Mar 5, 2019 | $1.66M |
| Sep 30, 2018 | -$0.31 | -$0.28 | -$0.36 - -$0.10 | -10.71% | Miss | N/A | 7 | N/A | Nov 1, 2018 | $1.03M |
| Jun 30, 2018 | -$0.37 | -$0.32 | -$0.38 - -$0.18 | -15.63% | Miss | N/A | 7 | N/A | Aug 6, 2018 | $1.03M |
| Mar 31, 2018 | -$0.27 | -$0.22 | -$0.25 - -$0.17 | -22.73% | Miss | N/A | 6 | N/A | May 10, 2018 | $1.03M |
| Dec 31, 2017 | -$0.29 | -$0.24 | -$0.27 - -$0.21 | -20.83% | Miss | N/A | 7 | N/A | Mar 5, 2018 | $1.03M |
| Sep 30, 2017 | -$0.25 | -$0.25 | -$0.26 - -$0.24 | 0.00% | In line | N/A | 5 | N/A | Nov 1, 2017 | $1.03M |
| Jun 30, 2017 | -$0.23 | -$0.23 | -$0.27 - -$0.20 | 0.00% | In line | N/A | 5 | N/A | Aug 14, 2017 | $1.03M |
| Mar 31, 2017 | -$0.24 | -$0.20 | -$0.22 - -$0.19 | -20.00% | Miss | N/A | 5 | N/A | May 15, 2017 | $1.03M |
| Dec 31, 2016 | -$0.21 | -$0.29 | N/A | +27.59% | Beat | N/A | N/A | N/A | Mar 16, 2017 | $1.03M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.15, after -$1.64 the year before. It was -$1.06 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.15 | N/A |
| Dec 31, 2024 | -$1.64 | N/A |
| Dec 31, 2023 | -$1.64 | N/A |
| Dec 31, 2022 | -$2.90 | N/A |
| Dec 31, 2021 | -$2.19 | N/A |
| Dec 31, 2020 | -$2.08 | N/A |
| Dec 31, 2019 | -$1.43 | N/A |
| Dec 31, 2018 | -$1.20 | N/A |
| Dec 31, 2017 | -$1.01 | N/A |
| Dec 31, 2016 | -$1.06 | N/A |
Frequently Asked Questions About FATE
When is Fate Therapeutics's next earnings date?
Fate Therapeutics's next earnings report is expected for Feb 24, 2027.
Did FATE beat earnings estimates last quarter?
Yes. Fate Therapeutics reported EPS of -$0.25 for the quarter ended Sep 30, 2026, above the -$0.27 estimate, a 7.41% surprise.
What EPS do analysts expect from FATE next quarter?
The consensus EPS estimate for Fate Therapeutics for the quarter ending Dec 31, 2026 is -$0.25 from 14 analysts, with estimates from -$0.27 to -$0.16.
How often does FATE beat earnings estimates?
Fate Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +6.94%.
FATE pages: Overview, Earnings, Forecast, Financials, Competitors